Drugs / MTX=Methotrexate
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03016013 Background | Mar 2017 → Nov 2022 | rheumatoid arthritis | RemeGen Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTX=Methotrexate | “MTX=Methotrexate” NCT03016013 ↗ |
| Known as | MTX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03016013 ↗ |
| Route | Subcutaneous | “Patients received the test group RC18 160mg plus MTX weekly administered subcutaneously for 24 times.” NCT03016013 ↗ |